文献速递类风湿关节炎

类风湿关节炎患者中CYP2E1和DUSP22启动子低甲基化与疾病活动度及侵蚀性病变相关

Hypomethylation of CYP2E1 and DUSP22 Promoters Associated With Disease Activity and Erosive Disease Among Rheumatoid Arthritis Patients.
PubMed 文献 · Arthritis Rheumatol · 2018-02-18

研究纳入加州大学旧金山分校类风湿关节炎队列63例患者,分选4种外周血免疫细胞亚群,用Illumina HumanMethylation450芯片生成229份全表观基因组DNA甲基化谱,发现CYP2E1和DUSP22基因启动子低甲基化区域分别与活动性疾病和侵蚀性疾病相关。

要点

  • 在全部4种免疫细胞亚型中均观察到与临床结局相关的CpG位点差异甲基化。
  • CYP2E1启动子低甲基化区域与活动性疾病相关,DUSP22启动子低甲基化区域与侵蚀性疾病相关。
  • 通路分析提示各临床结局背后的生物学机制具有细胞类型特异性。

核心结论

  • 针对类风湿关节炎临床结局的特异性甲基化特征可能作为暴露、疾病进展和疾病严重程度的生物标志物或预测因子。

研究设计与样本

  • 研究纳入加州大学旧金山分校类风湿关节炎队列63例患者,全部符合美国风湿病学会分类标准,其中57例类风湿因子和/或抗环瓜氨酸蛋白抗体阳性。
  • 采用荧光激活细胞分选将每例患者外周血细胞分为4种免疫细胞亚群(CD14+单核细胞、CD19+B细胞、CD4+初始T细胞、CD4+记忆T细胞),用Illumina HumanMethylation450 BeadChip生成229份全表观基因组DNA甲基化谱。
  • 采用稳健回归模型和经验贝叶斯方差估计器识别与临床疾病活动度指数评分、侵蚀性疾病、类风湿关节炎关节损伤评分、Sharp评分、采血时用药、吸烟状态和病程相关的差异甲基化位点和区域。

主要发现

  • 在全部4种细胞类型中均观察到与临床结局相关的CpG位点差异甲基化。
  • CYP2E1基因启动子低甲基化区域与活动性疾病相关,DUSP22基因启动子低甲基化区域与侵蚀性疾病相关。
  • 通路分析提示各临床结局背后的生物学机制具有细胞类型特异性。
  • 还识别出吸烟、用药和病程对DNA甲基化的独立效应证据。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Epigenetic modifications have previously been associated with rheumatoid arthritis (RA). In this study, we aimed to determine whether differential DNA methylation in peripheral blood cell subpopulations is associated with any of 4 clinical outcomes among RA patients. METHODS: Peripheral blood samples were obtained from 63 patients in the University of California, San Francisco RA cohort (all satisfied the American College of Rheumatology classification criteria; 57 were seropositive for rheumatoid factor and/or anti-cyclic citrullinated protein). Fluorescence-activated cell sorting was used to separate the cells into 4 immune cell subpopulations (CD14+ monocytes, CD19+ B cells, CD4+ naive T cells, and CD4+ memory T cells) per individual, and 229 epigenome-wide DNA methylation profiles were generated using Illumina HumanMethylation450 BeadChips. Differentially methylated positions and regions associated with the Clinical Disease Activity Index score, erosive disease, RA Articular Damage score, Sharp score, medication at time of blood draw, smoking status, and disease duration were identified using robust regression models and empirical Bayes variance estimators. RESULTS: Differential methylation of CpG sites associated with clinical outcomes was observed in all 4 cell types. Hypomethylated regions in the CYP2E1 and DUSP22 gene promoters were associated with active and erosive disease, respectively. Pathway analyses suggested that the biologic mechanisms underlying each clinical outcome are cell type-specific. Evidence of independent effects on DNA methylation from smoking, medication use, and disease duration were also identified. CONCLUSION: Methylation signatures specific to RA clinical outcomes may have utility as biomarkers or predictors of exposure, disease progression, and disease severity.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Mok A, Rhead B, Holingue C, et al. Hypomethylation of CYP2E1 and DUSP22 Promoters Associated With Disease Activity and Erosive Disease Among Rheumatoid Arthritis Patients. Arthritis Rheumatol. 2018. PMID: 29287311. doi:10.1002/art.40408

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。